Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial.
By H. Abed, Gary Wittert, D. Leong, Masoumeh G. Shirazi, Bobak Bahrami, M. Middeldorp, M. Lorimer, D. Lau, N. Antic, A. Brooks and 3 more. Journal of the American Medical Association (JAMA), 2013
734 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine
View Paper: https://www.semanticscholar.org/paper/42155d11b474f5ee59e08c49f20db90a20367e1d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
Citations in the corpus
- The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. (2018, background): “As such, weight loss is an integral part in the multidisciplinary treatment of patients with AF and obesity.(421)”
- Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. (2014, background): “A recent study observed that weight and cardiometabolic RFM in overweight individuals with AF resulted in a reduction of the AF symptom burden (39).”
- Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up Study (LEGACY). (2015, methodology): “Our previous work demonstrated that shortterm weight loss and other risk factor management resulted in a reduction of the AF burden (14,15).”
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. (2016, neutral): “3), management of concomitant cardiovascular conditions can reduce symptom burden in AF and facilitate the maintenance of sinus rhythm.(203,204,296,312) This includes weight reduction,”